Esin, E. Et Al. 2019. Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naive breast cancer: real-life practice outcomes. CANCER CHEMOTHERAPY AND PHARMACOLOGY , vol.83, no.1 , 131-143.

Esin, E., Oksuzoglu, B., Bilici, A., ÇİÇİN, İ., KÖSTEK, O., Kaplan, M. A., ... AKSOY, S.(2019). Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naive breast cancer: real-life practice outcomes. CANCER CHEMOTHERAPY AND PHARMACOLOGY , vol.83, no.1, 131-143.

Esin, Ece Et Al. "Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naive breast cancer: real-life practice outcomes," CANCER CHEMOTHERAPY AND PHARMACOLOGY , vol.83, no.1, 131-143, 2019

Esin, Ece Et Al. "Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naive breast cancer: real-life practice outcomes." CANCER CHEMOTHERAPY AND PHARMACOLOGY , vol.83, no.1, pp.131-143, 2019

Esin, E. Et Al. (2019) . "Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naive breast cancer: real-life practice outcomes." CANCER CHEMOTHERAPY AND PHARMACOLOGY , vol.83, no.1, pp.131-143.

@article{article, author={Ece Esin Et Al. }, title={Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naive breast cancer: real-life practice outcomes}, journal={CANCER CHEMOTHERAPY AND PHARMACOLOGY}, year=2019, pages={131-143} }